Skip to main content

Advertisement

SpringerLink
Log in

Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy–refractory extensive-stage SCLC: a real-world retrospective study

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Great individual differences were observed regarding the efficacy of apatinib clinically. The aim of present study was to investigate the influence of vascular endothelial growth factor receptor2 (VEGFR2) gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy–refractory extensive-stage small cell lung cancer (ES-SCLC).

Methods

A total of 128 patients with chemotherapy–refractory ES-SCLC who were treated with apatinib at an initial dosage of 250 or 500 mg were included in this study. The change of target lesions was assessed. Overall response rate (ORR) was evaluated. Prognosis was carried out and safety profile was documented. Additionally, peripheral blood and biopsy cancer tissue specimens of the patients with SCLC were collected for the analysis of polymorphism and VEGFR2 gene mRNA expression, respectively. The association between genotype status and baseline characteristics was performed. Univariate analysis of genotype status and prognosis was carried out using Kaplan–Meier survival analysis and multivariate analysis were adjusted by Cox regression analysis.

Results

Efficacy of apatinib included partial response (PR) in 15 patients, stable disease (SD) in 86 patients, progressive disease (PD) in 27 patients. Therefore, ORR of the 128 patients with ES-SCLC was 11.7%, and disease control rate (DCR) was 78.9%. Prognosis suggested that the median progression-free survival (PFS) and overall survival (OS) of the 128 patients with ES-SCLC was 4.2 months and 8.2 months, respectively. The polymorphism analysis focusing on VEGFR2 gene indicated that one single nucleotide polymorphism 889C>T was of clinical significance. Prevalence of 889C>T among the 128 patients with SCLC were as follows: CC genotype 87 cases (68.0%), CT genotype 38 cases (29.7%) and TT genotype 3 cases (2.3%), the minor allele frequency of 889C>T was 0.17, which was in accordance with Hardy–Weinberg Equilibrium (P = 0.628). Patients with CT and TT genotypes were merged in the subsequent analysis. Prognosis analysis exhibited that the median PFS of patients with CT/TT genotype and CC genotype was 3.3 and 5.0 months, respectively (P = 0.02). Furthermore, the median OS of patients was 5.5 and 9.0 months, respectively (P = 0.008). Additionally, multivariate Cox regression analysis of OS demonstrated that CT/TT genotype was an independent factor for OS [Hazard ratio (HR) = 0.64, P = 0.019]. However, the safety profile according to genotype status of 889C>T failed to show significant difference. Interestingly, mRNA expression analysis suggested that the mRNA expression of VEGFR2 in cancer tissues were significantly different according to CC and CT/TT genotypes (P < 0.001).

Conclusion

The administration with apatinib for patients with chemotherapy–refractory ES-SCLC was of potential clinical significance. The clinical outcomes of patients with ES-SCLC who were treated with apatinib could be impacted by VEGFR2 889C>T polymorphism through mediating the VEGFR2 mRNA expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Saltos A, Antonia S (2020) Breaking the impasse: advances in treatment of small cell lung cancer. Clin Chest Med 41:269–280

    PubMed  Google Scholar 

  2. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

    Article  Google Scholar 

  3. Yu L, Lai Q, Gou L et al (2020) Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer. J Drug Target 1–11. https://doi.org/10.1080/1061186x.2020.1797050

  4. Jones GS, Elimian K, Baldwin DR et al (2020) A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung Cancer 141:44–55

    PubMed  Google Scholar 

  5. Dómine M, Moran T, Isla D et al (2020) SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol 22:245–255

    PubMed  Google Scholar 

  6. Eckardt JR, von Pawel J, Pujol JL et al (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–2092

    PubMed  CAS  Google Scholar 

  7. Ott PA, Elez E, Hiret S et al (2017) Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase ib KEYNOTE-028 study. J Clin Oncol 35:3823–3829

    PubMed  CAS  Google Scholar 

  8. Antonia SJ, López-Martin JA, Bendell J et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883–895

    PubMed  CAS  Google Scholar 

  9. Tay RY, Heigener D, Reck M et al (2019) Immune checkpoint blockade in small cell lung cancer. Lung Cancer 137:31–37

    PubMed  Google Scholar 

  10. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18

    CAS  Google Scholar 

  11. Dowell JE, Amirkhan RH, Lai WS et al (2004) Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2. Anticancer Res 24:2367–2373

    PubMed  CAS  Google Scholar 

  12. Tiseo M, Boni L, Ambrosio F et al (2017) Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol 35:1281–1287

    PubMed  CAS  Google Scholar 

  13. Li H, Zeng J, Jin X et al (2019) Apatinib for chemotherapy–refractory extensive-stage SCLC: a retrospective study. Cancer Chemother Pharmacol 83:1083–1090

    PubMed  Google Scholar 

  14. Ying Cheng QW, Li K et al (2018) OA13.03 Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind phase 2 trial. J Thorac Oncol 13:S351–S352

    Google Scholar 

  15. Li J, Qin S, Xu J et al (2016) Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy–refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 34:1448–1454

    PubMed  CAS  Google Scholar 

  16. Xu Y, Huang Z, Lu H et al (2019) Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. Br J Cancer 121:640–646

    PubMed  PubMed Central  CAS  Google Scholar 

  17. Wu F, Zhang S, Xiong A et al (2018) A Phase II clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer. Clin Lung Cancer 19:e831–e842

    PubMed  CAS  Google Scholar 

  18. Liu Y, Hu X, Jiang J et al (2020) A prospective study of apatinib in patients with extensive-stage small cell lung cancer after failure of two or more lines of chemotherapy. Oncologist 25:e833–e842

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Gitlitz BJ, Moon J, Glisson BS et al (2010) Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 5:1835–1840

    PubMed  PubMed Central  Google Scholar 

  20. Fan M, Zhang J, Wang Z et al (2014) Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat 143:141–151

    PubMed  CAS  Google Scholar 

  21. Song ZZ, Zhao LF, Zuo J et al (2020) Clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer in patients who progressed after standard therapy and analysis of the KDR gene polymorphism. Onco Targets Ther 13:603–613

    PubMed  PubMed Central  CAS  Google Scholar 

  22. Liu JY, Zhu BR, Wang YD et al (2020) The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. Int J Clin Oncol 25:1195–1205

    PubMed  CAS  Google Scholar 

  23. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    CAS  Google Scholar 

  24. Miller TP, Fisher BT, Getz KD et al (2019) Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer 66:e27747

    PubMed  PubMed Central  Google Scholar 

  25. Wu D, Nie J, Hu W et al (2020) A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer 147:3453–3460

    PubMed  PubMed Central  CAS  Google Scholar 

  26. Park S, Lee H, Lee B et al (2019) DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC. J Thorac Oncol 14:1640–1650

    PubMed  CAS  Google Scholar 

  27. Stratigos M, Matikas A, Voutsina A et al (2016) Targeting angiogenesis in small cell lung cancer. Transl Lung Cancer Res 5:389–400

    PubMed  PubMed Central  Google Scholar 

  28. Kim HC, Song JS, Lee JC et al (2014) Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer. Int J Clin Exp Pathol 7:6743–6751

    PubMed  PubMed Central  Google Scholar 

  29. Shaw V, Bullock K, Greenhalf W (2016) Single-nucleotide polymorphism to associate cancer risk. Methods Mol Biol 1381:93–110

    PubMed  CAS  Google Scholar 

  30. Wang C, Yang D, Zhang X et al (2020) Association of PTEN gene SNPs rs2299939 with PFS in patients with small cell lung cancer treated with early radiotherapy. Front Genet 11:298

    PubMed  PubMed Central  CAS  Google Scholar 

  31. Kim JH, Lee SY, Choi JE et al (2020) Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients. Thorac Cancer 11:19–28

    PubMed  CAS  Google Scholar 

  32. Anai S, Iwama E, Yoneshima Y et al (2018) Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. Lung Cancer 126:156–161

    PubMed  Google Scholar 

  33. Foster NR, Mandrekar SJ, Schild SE et al (2009) Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of north central cancer treatment group trials. Cancer 115:2721–2731

    PubMed  PubMed Central  CAS  Google Scholar 

  34. Rades D, Motisi L, Veninga T et al (2019) Predictors of outcomes and a scoring system for estimating survival in patients treated with radiotherapy for metastatic spinal cord compression from small-cell lung cancer. Clin Lung Cancer 20:322–329

    PubMed  Google Scholar 

  35. Wang S, Zimmermann S, Parikh K et al (2019) Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc 94:1599–1622

    PubMed  Google Scholar 

  36. Scartozzi M, Faloppi L, Svegliati Baroni G et al (2014) VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 135:1247–1256

    PubMed  CAS  Google Scholar 

  37. Gerger A, El-Khoueiry A, Zhang W et al (2011) Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 17:5783–5792

    PubMed  PubMed Central  CAS  Google Scholar 

  38. Schacher NM, Raaz-Schrauder D, Pasutto F et al (2019) Impact of single nucleotide polymorphisms in the VEGFR2 gene on endothelial cell activation under non-uniform shear stress. Int J Mol Med 44:1366–1376

    PubMed  PubMed Central  CAS  Google Scholar 

  39. Du Y, Chen Q, Huang L et al (2018) VEGFR2 and VEGF-C suppresses the epithelial-mesenchymal transition Via YAP in retinal pigment epithelial cells. Curr Mol Med 18:273–286

    PubMed  CAS  Google Scholar 

  40. Wang J, Taylor A, Showeil R et al (2014) Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Cytokine 68:94–100

    PubMed  CAS  Google Scholar 

  41. Cho HD, Moon KD, Park KH et al (2018) Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food Chem Toxicol 121:612–621

    PubMed  CAS  Google Scholar 

  42. Lu Y, Xu Q, Zuo Y et al (2017) Isoprenaline/beta2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. BMC Cancer 17:875

    PubMed  PubMed Central  Google Scholar 

  43. Jinesh GG, Manyam GC, Mmeje CO et al (2017) Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep 7:9602

    PubMed  PubMed Central  Google Scholar 

  44. Ding M, Liu L, Hu C et al (2014) Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res 26:669–677

    PubMed  PubMed Central  Google Scholar 

  45. Dang YZ, Zhang Y, Li JP et al (2017) High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer. Med (Baltimore) 96:e5772

    CAS  Google Scholar 

  46. Yan JD, Liu Y, Zhang ZY et al (2015) Expression and prognostic significance of VEGFR-2 in breast cancer. Pathol Res Pract 211:539–543

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to express our sincere gratitude to the patients and their relatives for agreeing to participate in this work.

Funding

This work was supported by the Key Program of Medical Science Research of Hebei Province, No. 20160160.

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, 12 Jian-Kang Road, Shijiazhuang, 050012, People’s Republic of China

    Nan Geng, Cui-Min Ding, Shan Song & Wen-Xia Hu

  2. Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People’s Republic of China

    Zhi-Kun Liu

Authors
  1. Nan Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cui-Min Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhi-Kun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wen-Xia Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen-Xia Hu.

Ethics declarations

Conflict of interest

All authors declare that there is no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee of The Fourth Hospital of Hebei Medical University.

Informed consent

The written informed consent was obtained from all the patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Geng, N., Ding, CM., Liu, ZK. et al. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy–refractory extensive-stage SCLC: a real-world retrospective study. Int J Clin Oncol 26, 670–683 (2021). https://doi.org/10.1007/s10147-020-01849-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-020-01849-w

Keyword

Search

Navigation